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Introduction: Multidrug-resistant protein-3 (MRP3), a membrane-
bound transporter, facilitates efflux of toxic compounds, including
certain chemotherapies, out of cells. Aberrant MRP3 expression has
been linked to drug resistance in non-small cell lung carcinoma
(NSCLC). We sought to determine if tumor MRP3 expression
patterns correlate with the mutational status of upstream regulators,
including nuclear factor erythroid-2-related factor 2 (Nrf2) and its
functional repressor Keap1 in NSCLC cell lines and patient samples.
Methods: To identify putative Nrf2-binding sites in the MRP3
promoter and to evaluate Keap1, Nrf2, and p53 mutation status in
four cell lines and 33 NSCLC surgically resected tumor specimens
with regard to their impact on MRP3 levels.
Results: Chromatin immunoprecipitation analysis of the MRP3 pro-
moter revealed an almost threefold increase in Nrf2 binding to the third
putative Nrf2-binding sequence distal to the start site, demonstrating
direct regulation ofMRP3 by Nrf2. In NSCLC cell lines, elevated Nrf2
protein was observed in cell lines with increased MRP3 RNA expres-
sion. In patient tumor specimens, the presence of mutations in Keap1/
Nrf2 correlated withMRP3 RNA levels (p 0.05). p53 mutations were
observed in 33% of cases, and all Keap1 mutant-positive tumors
possessed a p53 mutation (n  5; p  0.0019).
Conclusions: We demonstrate direct involvement between the tran-
scription factor Nrf2 and the MRP3 promoter, which leads to the
up-regulation of the MRP3 gene. In addition, we found a statistically
significant correlation between the presence of Keap1/Nrf2 mutations and
increased MRP3 messenger RNA levels in our NSCLC patient samples.
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(J Thorac Oncol. 2012;7: 34–39)
Multidrug-resistant proteins (MRPs) are a nine-memberbranch of the ATP-binding cassette superfamily.1 The role
of MRP3 is to facilitate transport of toxic compounds out of
cells; however, this increased transport can contribute to the
chemoresistance of cancer cells.2 Chemotherapy, radiation, and
xenobiotic stresses have been shown to induce levels of select
MRPs as part of a stress response program. Three members of
the MRP family, MRPs 1 to 3, have been associated with
increased resistance to chemotherapeutic compounds and are
thought to play a role in drug resistance of non-small cell lung
carcinoma (NSCLC).3,4 MRP1 levels have been reported to
increase with NSCLC cancer stage and invasiveness.5,6 MRP3 is
the closest structural ABCC family member to MRP1 (58%
homology).3 MRP3 protein levels have been correlated with
decreased sensitivity of lung cancer cell lines to doxorubicin,
vincristine, etoposide, and cisplatin.4 In addition, MRP3 expres-
sion correlates with increased resistance to methotrexate and
doxorubicin in NSCLC cell lines and patient tumor samples.2,3
The current accepted model for nuclear factor erythroid-
2-related factor 2 (Nrf2) regulation is one in which two amino-
terminal motifs in the Neh2 domain, a weak binding DLG motif
and a strong binding ETGEmotif, act as binding sites for Keap1,
which in turn promotes ubiquitination and rapid degradation;
also known as the hinge and latch model.7 We and others have
demonstrated that inhibition of Nrf2 decreases resistance to
chemotherapeutic agents.8,9 Furthermore, Shibata et al.7 found
that Nrf2 mutations occurred in approximately 11% of lung
cancer samples, with a striking frequency in the Neh2 domain,
and that these patients had a poor prognosis. Keap1, the key
functional repressor of Nrf2, is composed of an N-terminal
region (AA 1–60), a Broad complex, Tramtrack, and Bric-a-
Brac (BTB) domain (AA 61–179), a central intervening region
(IVR) (AA 180–314), six Kelch motifs (AA 315–359, 361–410,
412–457, 459–504, 506–551, and 553–598), and a C-terminal
domain (AA 599–624).10 Singh et al.10 found that Keap1
loss-of-function mutations occurred in approximately 19% of
NSCLC tumors and 50% of NSCLC cell lines examined. In
NSCLC cell lines with mutant (mt)Keap1, Nrf2 was found to be
constitutively active, and MRP1 and 2 expression was ele-
vated.10 In addition to enhanced drug resistance, Keap1mts may
also possess rapid growth characteristics.11 The goals of this
study were (1) to determine whether Nrf2 interacts with the
putative (electrophilic response element [EpRE]) binding sites
located434,628,805, and1049 base pair (bp) upstream
of the MRP3 promoter; and (2) to determine whether tumor
MRP3 expression patterns correlate with the mutational status of
Keap1, Nrf2, and p53 in NSCLC cell lines and patient samples.
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MATERIALS AND METHODS
Chemicals and Reagents
Unless otherwise noted, all chemicals were obtained
from Sigma (St. Louis, MO). Rabbit Nrf2 antibodies at 1/200
(sc-722) and mouse -actin antibody at 1:10,000 (A5441;
Sigma) were obtained from Santa Cruz Biotechnology (Santa
Cruz, CA). DNA-free reagents were obtained from Fermentas
(Glen Burnie, MD). TaqMan Reverse Transcription Reagent
and SYBR Green PCR Master Mix were obtained from
Applied Biosystems (Foster City, CA).
Cell Culture and Treatments
The cell lines H358 (p53 null/Keap1 wt), H1666 (p53
wt/Keap1 wt), A549 (p53 wt/Keap1 mt), H1650 (p53 wt/
Keap1 wt), and DU-145 (p53 mt/Keap1 wt*) were obtained
from the ATCC (Manassas, VA) and maintained in Roswell
Park Memorial Institute medium 1640 (Biowhittaker, Walkers-
ville, MD) supplemented with 10% heat-inactivated fetal bovine
serum (Omega Scientific, Tarzana, CA) to which was added
MEM Essential Vitamin Mix, Penicillin-Streptomycin, and
L-Glutamine. All cultures were grown at 37°C in 5% CO2
atmosphere. Cells were plated on 60-mm cell culture dishes at a
density of 300,000 cells per dish. Cells were treated at approx-
imately 70% confluence. Agents were diluted to appropriate
concentrations in media before use.
Reverse Transcription-Polymerase Chain Reaction
The content of MRP3 and -actin messenger RNA
(mRNA) was determined with real-time reverse transcription-
polymerase chain reaction (PCR) method. RNA samples
were treated with DNA-free reagent and reverse transcribed
by using the TaqMan reverse transcription system. Real-time
PCR was performed with a BioRad iQ5 iCycler PCR machine
(Hercules, CA). -actin was used as internal control. The
primers are as follows: MRP3—forward 5-CAGAGAAGG
TGCAGGTGACA-3, reverse 5-CTAAAGCAGCATA GA
CGCCC-3; -actin—forward 5-TGGGTGTGAACCATG
AGAAG-3, reverse 5-CCATCACGACACAGTTTCC-3.
Single-Strand Conformation Polymorphism PCR
Analysis was performed in 25-l reactions using 1
AmpliTaq Gold PCR Master Mix (Applied Biosystems), 10
M of primers, and 1 l of genomic DNA. The primer
sequences for p53 exons 5 to 8 are as follows: p53 exon
5—forward 5-TTCAACTCTGTCTCCTTCT-3, reverse 5-
CAGCCCTGTCGTCTCTCCAG-3; p53 exon 6—forward
5-GCCTCTGATTCCTCACTGAT-3, reverse 5-TTAACC
CCTCCTCCCAGAGA-3; p53 exon 7—forward 5-CTT
GCCACAGGTCTCCCCAA-3, reverse 5-TGTGCAGGG
TGGCAAGTGGC-3; and p53 exon 8—forward 5-TTC
CTTACTGCCTCTTGCTT-3, reverse 5-CGCTTCTTG
TCCTGCTTGCT-3. PCR was performed in a BioRad PTC-
200 DNA Engine Thermal Cycler (BioRad) for 35 cycles at
95°C for 15 seconds, 55°C for 30 seconds, and 68°C for 60
seconds with a final extension at 68°C for 10 minutes. After
PCR, 5 l of PCR products were checked by gel electropho-
resis using ethidium bromide. Subsequently, 3 l of PCR
products was mixed with 3 l of single-strand conformation
polymorphism (SSCP) loading buffer (95% formamide, 5%
xylene, and 10 mg bromophenol blue), incubated at 95°C for
5 minutes, and immediately placed on ice. DNA samples
were electrophoresed using the Gene Gel Excel 12.5/24 Kit
(Amersham Pharmacia Biotech, Sweden) at 600 V for 90
minutes. Exons 5, 7, and 8 were run at 18°C, while exon 6
was run at 10°C. The GenePhor Elecotrophoresis Unit (Am-
ersham Pharmacia Biotech) was used for all SSCP reactions.
DNA samples were visualized by silver stain. Any exon
fragments migrating abnormally in SSCP gels were se-
quenced to define the base changes. The specific positions
and types of nucleotide changes were recorded.
Tumor Specimens
Institutional review board-approved NSCLC tumor tis-
sues were acquired from the University of California Davis
Cancer Center Specimen Repository. Specimens were col-
lected at the time of surgery, pathologically reviewed, and
annotated. Tissue was stored at 80°C until extraction of
DNA, RNA, and protein, as described.
Preparation of Frozen Tissue
Genomic DNA was extracted from minced tissue using
the QIAamp DNA extraction kit (Qiagen, Valencia, CA) ac-
cording to the manufacturer’s protocol. RNA was extracted
using Qiagen RNeasy Kit (Qiagen). Quantity and quality of both
RNA and DNA were determined using a ND-1000 spectropho-
tometer (NanoDrop Technologies, Wilmington, DE).
Western Blotting
Western blotting was performed as previously re-
ported.12 Briefly, soluble proteins were extracted with the
addition of radio immunoprecipitation assay lysis solution
(RIPA Buffer, Leupeptin, Aprotinin, PMSF, NaVO4 and
DNase, and Rnase-free). The lysates were cleared by centrif-
ugation at 12,000 rpm at 4°C for 15 minutes, and soluble
protein extracts were stored frozen at 80°C. Protein con-
centrations were quantitated from duplicate readings using a
modified Bradford assay (Bio-Rad Laboratories). Cell lysates
were diluted with RIPA lysis buffer to either 20 or 30 g/l
to facilitate equal loading of samples and added to electro-
phoresis sodium dodecyl sulfate sample buffer and boiled at
95°C for 5 minutes. Total cell extracts were separated by 10
or 15% sodium dodecyl sulfate-polyacrylamide gel electro-
phoresis gels using a mini-gel system (Bio-Rad Laboratories)
for 120 to 150 minutes. Proteins were transferred to nitrocel-
lulose membranes (Bio-Rad Laboratories) overnight at a
constant 40 V. Membranes were then blocked with a pow-
dered milk solution. Blots were incubated at room tempera-
ture for 1 hour with Nrf2 (1: 200) and mouse anti--actin
antibody (1:10,000). After washing, blots were incubated in
horseradish peroxidase-conjugated anti-mouse IgG or anti-
rabbit IgG antibodies (1:2500) (Promega, Madison, WI) in
tris-buffered saline with tween 20 (TBST) for 1 hour, fol-
lowed by incubation with enhanced chemiluminescence de-
tection reagents (ECL; Fisher Scientific, Pittsburgh, PA).
Membranes were exposed to Kodak XAR film, the film was
developed, and the results were interpreted.
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Chromatin Immunoprecipitation Assay
Chromatin immunoprecipitation (ChIP) assay was per-
formed following a protocol provided with the kit from
Millipore (Temecula, CA). Briefly, cells were incubated with
formaldehyde (final concentration is 1%) at room temperature
for 10 minutes. Cell pellet was lysed on ice for 10 minutes
and sonicated using a Branson sonifier 150 (Branson, Dan-
bury, CT) under conditions that cause DNA to be broken into
200- to 800-bp fragments (five sets of 10-second pulses on
wet ice with output power at 3). Sonicated cell lysate was
precleared with 60 l of protein G agarose, and the superna-
tant was used for immunoprecipitation with antibodies to
specific transcription factors overnight at 4°C. The protein/
DNA complex was collected with 60 ml of protein G agarose
and then it was washed and eluted from agarose in elution
buffer. Next, the crosslink of DNA/protein was reversed by
adding 5 M NaCl and incubating the mixture at 65°C for 5
hours. The DNA was extracted with Spin filter. Glyceralde-
hyde-3-phosphate dehydrogenase (GAPDH) was used as the
input control. The real-time PCR was run for 50 cycles under
the conditions: 95°C 25 seconds, 61°C 30 seconds, and 72°C
31 seconds. Primers used for PCR in the ChIP assay were as
follows: EpRE1—forward 5-AGCCAAGGAAGGAAA
CACCT-3, reverse 5-ATCTCTCAATCCCGCTGTTG-3;
EpRE2—forward 5-AGCCTTAGGAGGAGGACGAG-3,
reverse GAATCTTCCTCCCAGGGTTC; EpRE3—forward
5-AGTAGAGGCCCAGAGACGTG-3, reverse 5-GGG
TGTGTACCCGTGAGG-3; EpRE4—forward 5-CCAGTG
GTCTCTGGAACCTG-3, reverse 5-GT TCCTCTCCGG-
AGGTCAGT-3; and GAPDH—forward 5-TACTAGCGG
TTTTACGGGCG-3, reverse 5-TCGAACAGGAGGAGC
AGAGAGCGA-3.
DNA Sequencing
PCR primers for Keap1 sequencing13 are as follows:
Keap1 exon 2F1, 5-TGGTGGTGTTGCTTATCTTCTGG-
3; Keap1 exon 2R1, 5-TACCCTCAATGGACACCACCT
CC-3; Keap1 exon 2F2, 5-AAGGTGGTGCTGGCCTCA
TCCAG-3; Keap1 exon 2R2, 5-AGACAGTGATGAGCA
CTCGTCCA-3; Keap1 exon 3F1, 5-GGTGACTGGAG
AGTCAGCCCGTC-3; Keap1 exon 3 R1, 5-CTCCAGGTA
GCTGAGCGACTGTC-3; Keap1 exon3 F2, 5-TGCACA
AGCCCACGCAGGTGATG-3; Keap1 exon3 R2, 5-TTG
GGACTTGCCAGGAGCAGGAC-3; Keap1 exon 4F, 5-
CACGAAGGTCAGCTATAATGGCC-3; Keap1 exon 4R,
5-TCAGTTTCACCCCAGGATGGTAG-3; Keap1 exon
5F, 5-TCTCCCTCAAGGAGGTGATGGCT-3; Keap1 exon
5R, 5-GCAAAAGCAGTCCACAAAAGATG-3; Keap1
exon 6F, 5-GCTCTTGGATGTGGTGTGACAGG-3; and
Keap1 exon 6R, 5-CAATGATACTCCCCATTGGACTG-
3. Primers for Nrf2 sequencing7 are as follows: Nrf2 exon
2—forward 5-ACCATCAACAGTGGCATAATGTG-3, rev-
erse 5-GGCAAAGCTGGAACTCAAATCCAG-3. All DNA
sequencing was performed on an ABI 3730 Capillary Electro-
phoresis Genetic Analyzer using ABI BigDye Terminator v3.1
Cycle Sequencing chemistry.
Software
Scion Image software was used in this study to quan-
titate protein levels of western blots by deriving a ratio
between absorbance values. Qgene was used to quantitate
relative mRNA levels.
Statistics
Comparisons of variants between experimental groups
were conducted using one-way analysis of variance. Fisher’s
exact test was used to determine nonrandom associations. All
data are expressed as themean standard error of themean. In-Stat
softwarewas used for statistical analysis. Statistical significancewas
accepted when p less than 0.05. The Tukey-Kramer Multiple
comparisons test was used for comparison of mRNA levels.
RESULTS
Nrf2 Binds to an MRP3 Upstream EpRE
The genomic sequence of the human MRP3 gene
(ABCC3) revealed four EpRE sequences in the promoter region
from11 bp through1103 bp. EpRE-binding sites are located
434, 628, 805, and 1049 bp. The Nrf2-EpRE signaling
activator 4-hydroxy-2-nonenal (HNE) was used as a surrogate
for oxidative stress.14,15 We have previously demonstrated that
HNE caused increases of MRP3 mRNA and protein levels in a
Keap1-wt NSCLC cell line but not in Keap1-mt NSCLC cell
lines. As an extension of our previous work, we sought to further
establish the relationship of Nrf2 and MRP3.8 The interaction
between Nrf2 and the MRP3 promoter was elucidated by use of
a ChIP assay of the Nrf2/DNA complex. Nrf2 binding was
increased at the 805 bp EpRE after exposure to 10 M of
HNE for 3 hours (Figure 1). Increased Nrf2 binding was not
observed at other putative EpRE-binding sites.
Keap1 and Nrf2 Mutational Status Correlates
with MRP3 Levels in Patient NSCLC Specimens
The presence of mutations in Keap1, Nrf2, or p53 was
investigated in 33 surgically resected NSCLC tumor specimens
and 4 NSCLC cell lines (Figure 2A, B). Four homozygous and
one heterozygous Keap1 mutations were detected in the patient
samples. All were missense mutations: three homozygous G3T
transversions, one G3A transition, and one heterozygous
C3T transition. One Nrf2 exon 2 mutation, a heterozygous
missense G3A transition, was observed (Table 1). Eleven of
the patient samples were mt for p53 (33%), which were cross
checked with the IARC TP53 data base (www-p53.iarc.fr) and
are defined in Table 2. All five of the patient samples that were
mt for Keap1 also were mt for p53, a statistically significant
association albeit from a highly limited sample size (p 0.0019;
Figure 2C). Sequencing of Keap1 and Nrf2 in our cell line
models confirmed the homozygous mutation at amino acid 333
found by Singh et al. in A549; all other cell lines evaluated were
wild type for Keap1 and Nrf2.
MRP3 Levels Are Higher in Mt Keap1/Nrf2 Cell
Line and NSCLC Patient Samples
Levels of MRP3 mRNA were evaluated in four NSCLC
and one prostate cancer cell lines (Figure 3A), and mutational
status of Keap1, Nrf2, and p53 was analyzed in 33 surgical
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NSCLC specimens. Cell lines H1650 (Keap1 wt, p53 wt) and
H358 (Keap1 wt, p53 null) expressed relatively low levels of
MRP3 mRNA, whereas A549 (Keap1 mt, p53 wt) had high
levels of MRP3mRNA, consistent with their functional status of
Keap1. In contrast, H1666 (Keap1 wt, p53 wt) expressed high
levels of MRP3. We then evaluated the prostate cancer cell line
DU-145 (Keap1 wt, p53 mt), as it has recently been demon-
strated to produce low levels of Keap1 because of promoter
methylation and differentially spliced Keap1 mRNA. Total lev-
els of 67 KD Nrf2 were low in H1650 and H358 and high in
A549. In contrast, H1666 cells showed considerable levels of
110 KD Nrf2, which was also detected in DU-145 (Figure
3B). All tested cell lines had similar ratios of total Nrf2 protein
to MRP3 mRNA levels (H1650 Nrf2 levels were below level of
detection; Figure 3C). Patient tumor specimens were evaluated
for MRP3 levels with regard to their Keap1-Nrf2 functional
status. Those harboring a mutation in Keap1 or Nrf2 had signif-
icantly elevated MRP3 levels compared with wild-type speci-
mens (p  0.05) (Figure 4).
DISCUSSION
Chemotherapy, specifically platinum doublets, remains
the primary treatment for advanced NSCLC. Unfortunately,
NSCLCs have either acquired or inherent drug resistance.
Such multifactorial drug resistance is one contributing factor
to the abysmal 5-year survival rate for metastatic NSCLC,
which is just 2%. Chemoresistance is thought to be derived
by two principle mechanisms: the first involves an improved
capacity for DNA repair and the second involves up-regula-
tion of the cellular detoxification pathways such as the super
family of P-glycoproteins. Studies of clinical specimens and
cell lines have shown an increased capacity for drug trans-
port, and subsequent resistance, because of increased levels
of the multidrug resistance transporters and MRPs.
Our analysis of the human MRP3 gene revealed four
putative Nrf2-binding sites (EpREs) in the tentative promoter
region. This finding led us to hypothesize that activation of
Nrf2 could contribute to the induction of MRP3. ChIP anal-
ysis demonstrated increased Nrf2 binding to the 805 bp
EpRE after treatment with the Nrf2 activator, HNE. These
data, in conjunction with our previous work involving Nrf2
and MRP3 regulation, would strongly implicate direct in-
volvement of Nrf2 in the up-regulation of MRP3.8 In NSCLC
cell lines, total basal levels of MRP3 mRNA and Nrf2 protein
were concordant, showing a positive correlation. Although
the cell lines H1650, H358, and A549 had MRP3 mRNA
FIGURE 1. EpRE-binding sites are located 434, 628,
805, and 1049 bp. Nrf2 binding was increased 2.8-
fold versus control at the 805 bp EpRE after 3 hours expo-
sure to 15M HNE. EpRE, electrophilic response element;
Nrf2, nuclear factor erythroid-2-related factor 2; HNE,
4-hydroxy-2-nonenal.
FIGURE 2. (A) PCR amplification
of p53. Exons 5 to 8 were success-
fully amplified in patient samples.
(B) Single-strand conformation
polymorphism (SSCP). Mutations
were found in 11 of 33 samples
and confirmed by sequencing. (C)
The left column represents the
number of p53 wt patient samples
in our cohort (22/33), and the
right column is the number of p53
mt patient samples (11/33). All five
Keap1 mutations occurred in con-
junction with a p53 mutation;
Fisher’s exact test  two-sided p
value is 0.0019. PCR, polymerase
chain reaction; mt, mutant.
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levels that corresponded to our hypothesis based on their
respective mutational status, the NSCLC cell line H1666
(Keap1 wt, Nrf2 wt, p53 wt) had levels of MRP3 that
exceeded those of the Keap1 mt A549. Recent data from
Johns Hopkins University suggest an epigenetic explanation
for this finding: they demonstrated that hypermethylation of
the promoter and aberrant splicing of Keap1 mRNA occurred
in the Keap1 wt cell line DU-145, causing low levels of
Keap1, increased growth rates, and up-regulation of Nrf2-
controlled genes.16 We examined DU-145 and found modest
induction of MRP3. In addition, 110 KD Nrf2 was present
in only DU-145 and H1666. This variant of Nrf2 has been
previously reported and has been shown to be functionally
active. What precisely is modifying Nrf2 migration is a
subject of debate, with some evidence pointing to polyubiq-
uitination or actin complexes17,18 The prevalence of promoter
hypermethylation and aberrant splicing of Keap1 in NSCLC
patient populations could be of clinical relevance in defining
chemoresistant populations. Another potential contributor to
differences in basal Nrf2 activation that warrants further
exploration is the endogenous production of oxidants that has
been shown to be high in some cancer cells.19
Sequencing of Keap1 and the Neh2 domain of Nrf2 in 33
primary tumors from patients with lung cancer revealed mis-
sense mutations in a total of six tumors. Singh et al found a
frequency of Keap1 mutations of 18.5%, similar to our findings
of 15%. Shibata et al found approximately 11% of their patients
analyzed were Nrf2 mt, compared with our findings of 3%. All
but one of our mt patient specimens, the only sample of neu-
roendocrine histology, expressed high levels of MRP3. All of
the Keap1 mutations were found to occur in the kelch domains,
and intriguingly they all occurred in tumors that were also mt for
p53. The veracity of this latter finding in NSCLC will require
larger study populations. It has been demonstrated that human
lymphoblastoid cells that have mt p53 acquire new mutations at
a higher frequency.20 Patients who have mt p53 would conse-
quently have reduced ability to preserve genomic integrity; as
such one would expect these patients to acquire new mutations
at an increased rate over their p53wt counterparts. Alternatively,
the concurrence of p53 and Keap1 mutations may cooperate
synergistically to promote tumorigenesis.
Constitutive activation of Nrf2 has been demonstrated to
be involved in the up-regulation of a number of genes associated
with cellular detoxification, including the drug transporter
TABLE 1. Keap1 and Nrf2 Mutational Status
Cell Line/Sample Mutation Base Change Amino Acid Change Domain Tumor Histology Smoking Status
A549 Keap1/homo G3T G333C  nonpolar to polar First Kelch domain Adenocarcinoma Unknown
PT377 Keap1/homo G3T G333V  nonpolar to nonpolar First Kelch domain Metastatic Never
PT146 Keap1/homo G3A D422N  acidic to polar Third Kelch domain Squamous Current
PT135 Keap1/homo G3T W497C  non-polar to polar Fourth Kelch domain Neuroendocrine Former
PT423 Keap1/homo G3T A548S  nonpolar to polar Fifth Kelch domain Metastatic Former
PT373 Keap1/hetro C3T T598I  polar to nonpolar Sixth Kelch domain Adenocarcinoma Current
PT367 Nrf2/hetro G3A R43Q  basic to polar Neh2 Adenocarcinoma Never
TABLE 2. Patient Samples Containing a p53 Mutation
Sample p53 Mutation
PT377 E298X/E298X
PT373 Deletion-codons 244–246
PT126 P151S
PT421 D281E
PT140 Deletion-codons 158–161
PT423 G154V
PT369 C141G
PT135 R248Q
PT297 Insertion-codon 201
PT130 P190L
PT146 D259Y
FIGURE 3. (A) H1650 (p53 wt/Keap1 wt/Nrf2 wt), H358
(p53 null/Keap1 wt/Nrf2 wt), H1666 (p53 wt/Keap1 wt/Nrf2
wt), A549 (p53 wt/Keap1 mt/Nrf2 wt), and DU-145 (p53
mt/Keap1 wt*). Levels of MRP3 mRNA of our cell line model
are compared. (B) Western blot of standard and 110 KD
Nrf2 in our cell line model. (C) Scion image absorbance
measurements. Levels of total 67 KD and 110 KD Nrf2 as
a ratio to respective -actin levels. Horizontal lines  Keap1
wt, black  Keap1 mt, gray shading  Keap1 splicing errors.
Results are expressed as means  SEM (n  3). MRP3,
mRNA, messenger RNA; Nrf2, nuclear factor erythroid-2-
related factor 2; SEM, standard error of the mean.
Mahaffey et al. Journal of Thoracic Oncology • Volume 7, Number 1, January 2012
Copyright © 2011 by the International Association for the Study of Lung Cancer38
MRP3. Further studies are needed to determine the prevalence
of Keap1 inactivation in the patient population because of
mutation, transcriptional, and posttranscriptional mechanisms
such as splicing errors. Future directions of this work could lead
to: (A) identification and development of tools for screening of
tumor profiles that place patients with NSCLC at increased risk
for chemoresistance and metastasis, making this a prognostic
and a predictive marker; and (B) understanding the molecular
mechanisms that lead to clinically significant lung cancer could
lead to improved therapies. For example, patients with NSCLC
harboring a loss of either wt Keap1 could have improved benefit
from chemotherapy or radiotherapy when given in combination
with compounds designed to inhibit the Nrf2 pathway. This
research could lead to improve understanding of tumor genetic
interactions on NSCLC treatment efficacy and further provide
the proof-of-principle required for expanded basic, translation,
and clinical research that will have direct impact on patient care.
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FIGURE 4. Patient MRP3 mRNA levels were normalized to
those of H358. Keap1/Nrf2 wt patient samples (Mean 2.6-
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different (p  0.05). Results are expressed as means  SEM.
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